• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
Tal Zaks
November 1, 2021 10:52 AM EDT
People

Tal Zak­s' post-Mod­er­na fu­ture is now in view as he joins biotech VC blue-chip­per Or­biMed

Nicole DeFeudis

Editor

It’s hard to imag­ine what comes next for a physi­cian-sci­en­tist who’s de­vel­oped one of the most lu­cra­tive vac­cines in bio­phar­ma his­to­ry. On Mon­day — a month …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • 4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans July 3, 2025
  • Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal June 30, 2025
  • Trump’s CDC nom­i­nee side­steps Sen­ate grilling on con­tro­ver­sial changes June 25, 2025
TRENDING NOW

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

Ope­nAI-backed start­up re­leas­es new AI mod­els, claim­ing top per­for­mance in mak­ing an­ti­bod­ies

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times